Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1082943

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1082943

Global Breast Cyst Treatment Market - 2022-2029

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The global breast cyst treatment market is growing at a high CAGR during the forecast period (2022-2029).

Inside the breast, cysts are fluid-filled sacs. They are usually cancer-free (benign). Breast cysts can be single or multiple. A breast cyst feels like a grape or a water-filled balloon most of the time, but it can also be firm.

Market Dynamics

The factors influencing the global breast cyst treatment market are the increasing research and development and the growing prevalence of breast cysts.

The increasing research and development are expected to drive the market growth

Cysts appear to form due to fibrosis in the development of breast tissue and subsequent failure of the lobule and terminal ductule formation process. The physical mechanism is that fibrosis causes epithelial thickening, which causes the developing lobule to be involute early in its development. This causes the surrounding stroma to vanish and the adjoining ductule to collapse, resulting in an abnormal epithelial-lined fold that becomes completely walled off. Epithelial acinar secretions dilate the epithelial fold, transforming it into a self-contained fluid-filled cavity. Moreover, many studies show a high lifetime prevalence of fibrocystic breast disease in women. Over 70% of all women experience fibrocystic changes at some point in their lives, with 20% of these women becoming symptomatic and 10% -30% developing sclerosing adenosis. A palpable breast cyst is estimated to affect 7% of all women in the United States at some point in their lives. Breast cysts are most common in women aged 30 to 50. During these years, the incidence of cyst development rises and then falls dramatically. Most benign cysts disappear, and new cysts stop developing a year after menopause, as cyst development is linked to hormone levels in the body.

Limitations associated with breast cyst treatment are expected to hamper the market growth

The risks associated with Fine Needle Aspiration are minimal. The injection site has a small chance of bleeding and infection. The patient may be sore for a day or two after the procedure, and mild bruising and swelling may occur. Another disadvantage of fine needle aspiration is that the needle may miss a tumor and instead take a sample of healthy cells.

If this occurs, the biopsy will show that cancer does not exist when it does. A false negative result causes a delay in diagnosis. Fine needle aspirations of palpable lumps have a 2-4 percent low false-negative rate.

COVID-19 Impact Analysis

The market has suffered a minor setback due to the COVID-19 outbreak, owing to delays in diagnosis, drug shortages, and a lack of healthcare professionals. According to an article published in the JAMA Network in August 2020, between March 1, 2020, and April 18, 2020, there was a significant decrease in breast cancer treatment and diagnosis in the United States (by as much as 51.8 percent). As a result, the delay in diagnosing breast cancer has impacted treatment. In its early stages, the COVID-19 pandemic has had a negative impact on the breast cyst treatment market. However, as treatments are resumed worldwide, the market is expected to gain traction in the coming years.

Segment Analysis

Fine-needle aspiration segment is expected to dominate the market growth

If all the fluid in the cyst can be removed during the procedure, fine-needle aspiration can be used to diagnose and treat a breast cyst, and breast lump and symptoms disappear. However, some breast cysts may require more than one drainage procedure. Cysts that recur or form new cysts are common. If a breast cyst persists for two to three menstrual cycles and grows, it should be treated. A small amount of breast tissue or fluid is removed from a suspicious area with a thin, hollow needle and checked for cancer cells during a fine needle aspiration (FNA). If other tests indicate that you may have breast cancer, this type of biopsy may be an option (although a core needle biopsy is often preferred). lt can also be used in other contexts. The main benefits of FNA are that it is relatively quick, it rarely requires anesthesia, the skin is not cut, so no stitches are required, and there is usually no scar. In some cases, one can even get the results on the same day.

Moreover, on 20th April 2020, The FDA-approved Fisher's CytoCore fine needle device, which can be attached to a small needle, has an internal motor that rotates the needle during the biopsy.

Geographical Analysis

North America region is expected to hold the largest market share in the global breast cyst treatment market

The growing incidence of breast cysts and increasing research and development in this region is expected to drive the market growth in the forecast period.

A palpable breast cyst is estimated to affect 7% of all women in the United States at some point in their lives. Breast cysts are most common in women aged 30 to 50. Moreover, key players in this region are expected to drive market growth. For instance, Becton, Dickinson, and Company, or BD, is a multinational medical technology company based in the United States. The company's FNA needles are available with a Chiba or Franseen tip for maximum versatility when aspirating soft tissue masses.

Competitive Landscape

The global breast cyst treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Advin Health Care, Becton, Dickinson, and Company, Swastik Enterprise, Argon Medical Devices, Inc., SOMATEX Medical Technologies GmbH, Remington Medical Inc., HAKKO CO., LTD., BPB MEDICA

Becton, Dickinson, and Company

Overview: Becton, Dickinson, and Company, or BD, is a multinational medical technology company based in the United States that manufactures and sells medical devices, instrument systems, and reagents. In some areas, BD also offers consulting and analytics services.

Product Portfolio: The company's FNA needles are available with a Chiba or Franseen tip for maximum versatility when aspirating soft tissue masses.

Why Purchase the Report?

  • Visualize the composition of the global breast cyst treatment market segmentation by treatment type and end users highlighting the key commercial assets and players.
  • Identify commercial opportunities in global breast cyst treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global breast cyst treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global breast cyst treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Product Code: DMPH5389

Table of Contents

1. Breast Cyst Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Breast Cyst Treatment Market - Market Definition and Overview

3. Breast Cyst Treatment Market - Executive Summary

  • 3.1. Market Snippet By Treatment Type
  • 3.2. Market Snippet By End Users
  • 3.3. Market Snippet By Region

4. Breast Cyst Treatment Market -Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with breast cyst treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Breast Cyst Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Breast Cyst Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Breast Cyst Treatment Market -By Treatment Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.3. Market Attractiveness Index, By Treatment Type
    • 7.3.1. Fine Needle Aspiration*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Surgeries
    • 7.3.3. Radiotherapy
    • 7.3.4. Hormonal Therapy

8. Breast Cyst Treatment Market - By End Users

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 8.1.2. Market Attractiveness Index, By End Users
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Other

9. Breast Cyst Treatment Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

10. Breast Cyst Treatment Market - Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Breast Cyst Treatment Market - Company Profiles

  • 11.1. Becton, Dickinson and Company*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Advin Health Care
  • 11.3. Swastik Enterprise
  • 11.4. Argon Medical Devices, Inc.
  • 11.5. SOMATEX Medical Technologies GmbH
  • 11.6. Remington Medical Inc.
  • 11.7. HAKKO CO., LTD.
  • 11.8. BPB MEDICA

LIST NOT EXHAUSTIVE

12. Breast Cyst Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!